Clesrovimab (Enflonsia) for Prevention of Severe RSV Infection in Infants
August 18, 2025 (Issue: 1735)
The FDA has approved clesrovimab-cfor (Enflonsia –
Merck), a long-acting monoclonal antibody, for
prevention of respiratory syncytial virus (RSV) lower
respiratory tract infection (LRTI) in neonates and
infants born during or entering their...more
- Nirsevimab (Beyfortus) for prevention of severe RSV disease in young children. Med Lett Drugs Ther 2023; 65:145.
- CDC. Surveillance of RSV. July 8, 2025. Available at: https://bit.ly/3GDdznw. Accessed July 30, 2025.
- C Rosas-Salazar et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet 2023; 401:1669. doi:10.1016/s0140-6736(23)00811-5
- S Hamid et al. Seasonality of respiratory syncytial virus ― United States, 2017-2023. MMWR Morb Mortal Wkly Rep 2023; 72:355. doi:10.15585/mmwr.mm7214a1
- B Kampmann et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023; 388:1451. doi:10.1056/nejmoa2216480
- KE Fleming-Dutra et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1115. doi:10.15585/mmwr.mm7241e1
- JM Jones et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:920. doi:10.15585/mmwr.mm7234a4
- American Academy of Pediatrics. AAP recommendations for the prevention of RSV disease in infants and children. Red Book Online. July 8, 2025. Available at: https://bit.ly/40F6LMV. Accessed July 30, 2025.
- Merck News Release. ACIP recommends use of Merck’s ENFLONSIA (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age born during or entering their first RSV season. June 26, 2025. Available at: https://bit.ly/456h5Pn. Accessed July 30, 2025.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
